311 related articles for article (PubMed ID: 29048983)
21. Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics.
Varma T; Wallach JD; Miller JE; Schnabel D; Skydel JJ; Zhang AD; Dinan MA; Ross JS; Gross CP
JAMA Netw Open; 2021 Apr; 4(4):e217063. PubMed ID: 33877309
[TBL] [Abstract][Full Text] [Related]
22. Quantifying Clinical Trial Diversity in Pivotal Registration Trials of FDA Novel Drug Approvals.
Idris MY; Fitzsimmons WE; Pemu P
Ther Innov Regul Sci; 2024 Jan; 58(1):175-183. PubMed ID: 37872439
[TBL] [Abstract][Full Text] [Related]
23. Racial/Ethnic Disparities in Ophthalmology Clinical Trials Resulting in US Food and Drug Administration Drug Approvals From 2000 to 2020.
Berkowitz ST; Groth SL; Gangaputra S; Patel S
JAMA Ophthalmol; 2021 Jun; 139(6):629-637. PubMed ID: 33885724
[TBL] [Abstract][Full Text] [Related]
24. Demographic Composition of Select Oncologic New Molecular Entities Approved by the FDA Between 2008 and 2017.
Ramamoorthy A; Knepper TC; Merenda C; Mendoza M; McLeod HL; Bull J; Zhang L; Pacanowski M
Clin Pharmacol Ther; 2018 Nov; 104(5):940-948. PubMed ID: 30218447
[TBL] [Abstract][Full Text] [Related]
25. Sex, racial, and ethnic diversity in clinical trials.
Bøttern J; Stage TB; Dunvald AD
Clin Transl Sci; 2023 Jun; 16(6):937-945. PubMed ID: 36908052
[TBL] [Abstract][Full Text] [Related]
26. Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016.
Alexander GC; Ogasawara K; Wiegand D; Lin D; Breder CD
Ther Innov Regul Sci; 2019 Nov; 53(6):752-758. PubMed ID: 30509142
[TBL] [Abstract][Full Text] [Related]
27. Racial representation in clinical trials for dermatological new molecular entities.
Ha MV; Wong C
Clin Exp Dermatol; 2022 Feb; 47(2):386-388. PubMed ID: 34346107
[TBL] [Abstract][Full Text] [Related]
28. Diversity in Medical Device Clinical Trials: Do We Know What Works for Which Patients?
Fox-Rawlings SR; Gottschalk LB; Doamekpor LA; Zuckerman DM
Milbank Q; 2018 Sep; 96(3):499-529. PubMed ID: 30203600
[TBL] [Abstract][Full Text] [Related]
29. Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials: A Systematic Review.
Tahhan AS; Vaduganathan M; Greene SJ; Alrohaibani A; Raad M; Gafeer M; Mehran R; Fonarow GC; Douglas PS; Bhatt DL; Butler J
JAMA Cardiol; 2020 Jun; 5(6):714-722. PubMed ID: 32211813
[TBL] [Abstract][Full Text] [Related]
30. Minority Enrollment to Clinical Trials: Road to Increased Access.
Vose J
Oncology (Williston Park); 2021 Mar; 35(3):107. PubMed ID: 33818053
[TBL] [Abstract][Full Text] [Related]
31. An evaluation of race-based representation among men participating in clinical trials for prostate cancer and erectile dysfunction.
Saltzman RG; Zucker I; Campbell K; Gandhi DA; Otiono K; Weber A; Masterson TA; Ramasamy R
Contemp Clin Trials Commun; 2022 Oct; 29():100986. PubMed ID: 36092973
[TBL] [Abstract][Full Text] [Related]
32. Representation of sex, race, and ethnicity in pivotal clinical trials for dermatological drugs.
Ding J; Zhou Y; Khan MS; Sy RN; Khosa F
Int J Womens Dermatol; 2021 Sep; 7(4):428-434. PubMed ID: 34621955
[TBL] [Abstract][Full Text] [Related]
33. New Drug Formulary Management and Utilization: Evidence in Sex, Race, and Ethnicity: 2019-2020.
Keeys CA; Harding BW; Migneco GE; Rahini SS; Coleman HB
Ann Pharmacother; 2022 Feb; 56(2):139-145. PubMed ID: 34049437
[TBL] [Abstract][Full Text] [Related]
34. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
[TBL] [Abstract][Full Text] [Related]
35. Current issues surrounding women and minorities in drug trials.
Wermeling DP; Selwitz AS
Ann Pharmacother; 1993; 27(7-8):904-11. PubMed ID: 8364277
[TBL] [Abstract][Full Text] [Related]
36. Enrollment of racial/ethnic minorities and women with HIV in clinical research studies of HIV medicines.
Sullivan PS; McNaghten AD; Begley E; Hutchinson A; Cargill VA
J Natl Med Assoc; 2007 Mar; 99(3):242-50. PubMed ID: 17393948
[TBL] [Abstract][Full Text] [Related]
37. Missing data issues at the FDA Center for Biologics Evaluation and Research.
Scott JA; Hsu H
J Biopharm Stat; 2011 Mar; 21(2):196-201. PubMed ID: 21390996
[TBL] [Abstract][Full Text] [Related]
38. Quantifying Patient Subpopulation Disparities in New Drugs and Biologics Approved Between 2007 and 2017.
Getz KA; Smith ZP; Peña Y
Ther Innov Regul Sci; 2020 Nov; 54(6):1541-1550. PubMed ID: 32557009
[TBL] [Abstract][Full Text] [Related]
39. Increasing participation of women in early phase clinical trials approved by the FDA.
Pinnow E; Sharma P; Parekh A; Gevorkian N; Uhl K
Womens Health Issues; 2009; 19(2):89-93. PubMed ID: 19272558
[TBL] [Abstract][Full Text] [Related]
40. The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs.
Ladanie A; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
Trials; 2018 Sep; 19(1):505. PubMed ID: 30231912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
